Abstract:Primary Immunodeficiency disease (PIDD) comprise a group of disorders of immune function. Some of the most severe PIDD can be treated with hematopoietic cell transplant (HCT). Hizentra® is a 20% liquid IgG product approved for subcutaneous administration in adults and children greater than two years of age with PIDD-associated antibody deficiency. Limited information is available on use of Hizentra® in children following HCT for PIDD. A multicenter retrospective chart review demonstrated 37 infants and child… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.